Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,410 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00262886 | Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer | completed | Phase 2 | 35 | University of RochesterOTHER | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00045279 | PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00072150 | Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00091182 | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment | completed | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00354250 | Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00009867 | Arsenic Trioxide in Treating Patients With Urothelial Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00293527 | Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma | withdrawn | Phase 2 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | May 23, 2013 | clinicaltrials |
| NCT00425035 | Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2 | completed | Phase 2 | 115 | AmgenINDUSTRY | 0 | May 13, 2013 | clinicaltrials |
| NCT00491075 | Pemetrexed Plus Gemcitabine in Renal Cell Cancer | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2013 | clinicaltrials |
| NCT01616186 | Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | Andrea HarzstarkOTHER | 0 | Apr 8, 2013 | clinicaltrials |
| NCT00005027 | Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00011973 | Chemotherapy in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00003408 | Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer | completed | Phase 2 | 40 | Cancer Treatment Centers of AmericaOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT00021021 | RPI.4610 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | — | RibozyomeINDUSTRY | 1 | Mar 26, 2013 | clinicaltrials |
| NCT00182702 | Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00494091 | Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 82 | PfizerINDUSTRY | 3 | Mar 21, 2013 | clinicaltrials |
| NCT00490698 | Zoledronate With Atorvastatin in Renal Cell Carcinoma | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2013 | clinicaltrials |
| NCT00272649 | Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer | completed | Phase 1 / Phase 2 | 22 | Argos TherapeuticsINDUSTRY | 2 | Mar 14, 2013 | clinicaltrials |
| NCT00429026 | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | terminated | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00060307 | Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00101114 | Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00311545 | S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Feb 20, 2013 | clinicaltrials |
| NCT00087984 | RNA-Loaded Dendritic Cell Cancer Vaccine | completed | Phase 1 / Phase 2 | 26 | Argos TherapeuticsINDUSTRY | 2 | Feb 18, 2013 | clinicaltrials |
| NCT00619268 | Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma(TORAVA) | completed | Phase 2 | 160 | Centre Leon BerardOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00301847 | Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00003968 | Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2013 | clinicaltrials |
| NCT00557609 | Phase 2 Study in Patients With MiT Tumors | completed | Phase 2 | 47 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 3 | Feb 8, 2013 | clinicaltrials |
| NCT00193258 | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 94 | SCRI Development Innovations, LLCOTHER | 0 | Jan 31, 2013 | clinicaltrials |
| NCT00032188 | Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00009919 | SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00096525 | Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00006486 | Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 335 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00006968 | Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 4 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2013 | clinicaltrials |
| NCT00486538 | Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib | completed | Phase 2 | 53 | AbbVie (prior sponsor, Abbott)INDUSTRY | 2 | Jan 4, 2013 | clinicaltrials |
| NCT00328861 | Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 5, 2012 | clinicaltrials |
| NCT00058318 | S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer | completed | Phase 2 | 43 | SWOG Cancer Research NetworkNETWORK | 0 | Nov 2, 2012 | clinicaltrials |
| NCT00069160 | Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Oct 12, 2012 | clinicaltrials |
| NCT00787761 | Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer | completed | Phase 2 | 24 | Northside Hospital, Inc.OTHER | 1 | Oct 1, 2012 | clinicaltrials |
| NCT00031564 | Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2 | completed | Phase 2 | 49 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 27, 2012 | clinicaltrials |
| NCT00338884 | Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer | completed | Phase 2 | 120 | PfizerINDUSTRY | 6 | Aug 31, 2012 | clinicaltrials |
| NCT00030992 | BMS 247550 to Treat Kidney Cancer | completed | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2012 | clinicaltrials |
| NCT01158534 | Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery | completed | Phase 2 | 17 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00282048 | Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer | completed | Phase 2 | 62 | PfizerINDUSTRY | 1 | Jul 31, 2012 | clinicaltrials |
| NCT01070186 | Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 31, 2012 | clinicaltrials |
| NCT00088374 | 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease | completed | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2012 | clinicaltrials |
| NCT00523159 | IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease(IMA901-202) | completed | Phase 2 | 68 | Immatics Biotechnologies GmbHINDUSTRY | 10 | Jul 10, 2012 | clinicaltrials |
| NCT00076011 | Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 52 | PfizerINDUSTRY | 3 | Jun 26, 2012 | clinicaltrials |
| NCT00243009 | Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery | terminated | Phase 2 | 1 | OHSU Knight Cancer InstituteOTHER | 1 | May 28, 2012 | clinicaltrials |
| NCT00100685 | Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | terminated | Phase 2 | 48 | AbbottINDUSTRY | 1 | Apr 27, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jun 6, 2013source: clinicaltrials